Schedule 13D ownership disclosure
ENTASIS THERAPEUTICS HLDGS I
Security class unavailable · CUSIP: 293614103
Event date: 2020-07-02
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- Unavailable
- Percent of class
- 4.9000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-20-190493
- Form type
- SC 13D
- Filer
- Clarus Lifesciences III, L.P.
- CIK
- CIK 1597143
- Filed
- Jul 09, 2020
- Reporting period
- Jul 02, 2020
- Description
- Schedule 13D beneficial ownership